Evidence map›Paper›PMID 27629141›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.

Xiunan Li, Yumei Wu, Aihui Liu, Xin Tang

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 130 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Crosstalk between long noncoding RNA and microRNA in Cancer.Cellular oncology (Dordrecht, Netherlands) · 2023
    Review
  14. Review
  15. Interplay between LncRNAs and microRNAs in Breast Cancer.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Metformin and long non-coding RNAs in breast cancer.Journal of translational medicine · 2023
    Review
  18. Review
  19. Hypoxia-driven ncRNAs in breast cancer.Frontiers in oncology · 2023
    Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiunan LiDepartment of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100006, China.
Yumei WuDepartment of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 17#, Qihelou Street, Dongcheng District, Beijing, 100006, China. yumeiwu1@163.com.
Aihui LiuDepartment of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100006, China.
Xin TangDepartment of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100006, China.
Beijing Obstetrics and Gynecology Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies reported that long non-coding RNAs (lncRNAs) might play critical roles in regulating endocrine resistance of breast cancer. Urothelial carcinoma-associated 1 (UCA1) is an lncRNA with an oncogenic role in breast cancer. This study aimed to investigate whether UCA1 is involved in acquired tamoxifen resistance in estrogen receptor (ER)-positive cancer cells. Our findings reveal that tamoxifen induces UCA1 upregulation in ER-positive breast cancer cells in a HIF1α-dependent manner. UCA1 upregulation results in significantly enhanced tamoxifen resistance. The upregulated UCA1 sponges miR-18a, which is a negative regulator of HIF1α. Therefore, UCA1 upregulation is further enhanced through a miR-18a-HIF1α feedback loop. In addition, our data also showed that miR-18a is a modulator of tamoxifen sensitivity due to its regulative effect on cell cycle proteins. miR-18a inhibitor reduced the sensitivity of MCF-7 cells to tamoxifen, while miR-18a mimics sensitized BT474 cells to tamoxifen. Therefore, miR-18a downregulation also partly contributes to acquired tamoxifen resistance in the cancer cells. These findings provide some useful information for future clinical treatment of tamoxifen resistance.

Indexed as

Drug Resistance, NeoplasmGene Expression Regulation, NeoplasticAntineoplastic Agents, HormonalBlotting, WesternBreast NeoplasmsCell ProliferationComputational BiologyFemaleFlow CytometryHumansHypoxia-Inducible Factor 1, alpha SubunitImmunoprecipitationMicroRNAsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingAntineoplastic Agents, HormonalHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsMIRN18A microRNA, humanRNA, Long NoncodingRNA, MessengerTamoxifenUCA1 RNA, humanBreast cancerEndocrine resistanceHIF1αmiR-18aUCA1

Identifiers

PMID27629141
OpenAlexW2520617849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.